SCHEMBL10243908

SCHEMBL10243908

CCN(CCNC(=O)OC)C(C)c1ccc(OCC(=O)N2CCOCC2)cc1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FKBP1A P62942 8/20 0.59
POLB P06746 1/20 0.54
ALDH1A1 P00352 6/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
HPGD P15428 2/20 0.48
USP2 O75604 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.46
NPC1 O15118 2/20 0.46
LMNA P02545 2/20 0.46
NPSR1 Q6W5P4 1/20 0.45
MAPT P10636 2/20 0.45
TP53 P04637 1/20 0.45
TSHR P16473 1/20 0.45
MEN1 O00255 1/20 0.45
RAB9A P51151 1/20 0.45
KMT2A Q03164 1/20 0.45
KDM4E B2RXH2 1/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10244305 0.83 ALDH1A1 (0.42) POLBALDH1A1L3MBTL1SMN1; SMN2NPC1
SCHEMBL10243876 0.81 FKBP1A (0.65) FKBP1APOLBALDH1A1L3MBTL1HPGD
SCHEMBL10243580 0.80 ACACB (0.49) ALDH1A1HPGDSMN1; SMN2NPC1LMNA
SCHEMBL10244480 0.80 CYP1A2 (0.43) ALDH1A1HPGDSMN1; SMN2TP53TSHR
SCHEMBL10244823 0.79 MAPK1 (0.49) POLBALDH1A1L3MBTL1SMN1; SMN2LMNA
SCHEMBL10244037 0.78 CYP1A2 (0.46) ALDH1A1HPGDSMN1; SMN2NPC1NPSR1
SCHEMBL10243906 0.75 HDAC3 (0.44) HPGDNPC1LMNANPSR1MAPT
SCHEMBL10243525 0.75 ALOX5 (0.54) L3MBTL1SMN1; SMN2NPC1MAPTRAB9A
SCHEMBL10244408 0.75 PAX8 (0.43) POLBALDH1A1SMN1; SMN2LMNANPSR1
SCHEMBL10243510 0.74 ALOX5 (0.40) ALDH1A1L3MBTL1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 FKBP1A 2222/4885POLB 3348/4885ALDH1A1 1939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.